Attached files

file filename
EX-99.1 - THRESHOLD PHARMACEUTICALS INCv208960_ex99-1.htm
 


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 


FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 25, 2011 (January 24, 2011)


THRESHOLD PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

Delaware
001-32979
94-3409596
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)

1300 Seaport Boulevard, Suite 500
Redwood City, California 94063
(Address of principal executive offices)(Zip Code)

(650) 474-8200
(Registrant’s telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 


 
 
 

Item 8.01 
Other Events.
 
On January 24, 2011, Threshold Pharmaceuticals, Inc. issued a press release announcing clinical trial results related to Threshold’s clinical stage hypoxia-activated prodrug, TH-302.  The press release is attached as Exhibit 99.1 to this Form 8-K.
 

Item 9.01 
Financial Statements and Exhibits.

(d)
Exhibits

Exhibit 99.1
Press release dated January 24, 2011.
 
 
 

 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
     
  THRESHOLD PHARMACEUTICALS, INC.  
     
       
 
By:
/s/ Joel A. Fernandes  
    Joel A. Fernandes  
    Senior Director, Finance and Controller  
       
Date: January 25, 2011
 
 
 

 
 
Exhibit Index
 
Exhibit No.
 
Description
     
Exhibit 99.1
 
Press release dated January 24, 2011.